Moloney Securities Asset Management LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Moloney Securities Asset Management LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 9,712 shares of the medical equipment provider's stock, valued at approximately $1,066,000.

Several other institutional investors have also added to or reduced their stakes in LNTH. Citizens National Bank Trust Department grew its stake in Lantheus by 2.4% in the third quarter. Citizens National Bank Trust Department now owns 12,798 shares of the medical equipment provider's stock worth $1,405,000 after purchasing an additional 298 shares during the period. Van ECK Associates Corp raised its stake in Lantheus by 58.6% during the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock valued at $6,469,000 after buying an additional 21,604 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Lantheus by 56.0% in the third quarter. Harbor Capital Advisors Inc. now owns 128,913 shares of the medical equipment provider's stock worth $14,148,000 after buying an additional 46,262 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Lantheus by 226.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 526 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of Lantheus in the third quarter worth about $272,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In related news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares of the company's stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $23.79 during midday trading on Wednesday, hitting $91.17. The stock had a trading volume of 5,740,326 shares, compared to its average volume of 981,499. The stock has a 50 day moving average price of $108.41 and a two-hundred day moving average price of $95.60. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a market capitalization of $6.33 billion, a PE ratio of 15.36 and a beta of 0.51. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. Truist Financial reduced their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. Finally, Leerink Partners raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.